Oncology Company Announces FDA Clearance of New Solid Tumor Treatment
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors.
FibroGen, Inc. (NASDAQ:FGEN) recently announced a milestone in its oncology pipeline. The U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for FG-3165, a novel galectin-9 (Gal9) targeted monoclonal antibody. This clearance allows FibroGen to initiate clinical trials aimed at evaluating the safety and efficacy of FG-3165 in treating patients with solid tumors characterized by high Gal9 levels of expression. $FibroGen (FGEN.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
